Tambocor (flecainide) is a class Ic agent that specifically blocks fast-sodium channels, providing rapid conduction slowing. Unlike class III drugs that prolong repolarisation, flecainide’s effect is primarily on the initial depolarisation phase, making it useful for certain supraventricular arrhythmias where other classes may be less effective.
Many antihypertensives, such as ACE inhibitors, do not directly interact with flecainide. However, beta-blockers or calcium-channel blockers can amplify conduction slowing, so a clinician should review all cardiovascular drugs before combining them.
Oral flecainide is absorbed within a few hours; patients often notice a reduction in palpitations or irregular beats within 2-4 hours of the first dose, but full therapeutic effect may require several days of consistent dosing.
In the UK, the 50 mg flecainide tablet typically bears a specific imprint and colour defined by the manufacturer. Patients should check the packaging or consult their pharmacist for exact identification details.
Flecainide is not a controlled substance and is not screened for in standard workplace drug tests. Routine occupational testing should not flag the medication.
Yes, provided you carry a copy of the prescription and the original pharmacy label. Some countries may require declaration of prescription medicines at customs; checking the destination’s regulations beforehand is advisable.
If you miss a dose and the next scheduled dose is more than 4 hours away, take the missed tablet. If the next dose is sooner, skip the missed tablet and resume the regular schedule. Do not double the dose.
Yes, flecainide is marketed under several generic names once the original brand patent expires. The generic versions contain the same active ingredient and strengths (50 mg, 100 mg) and are interchangeable under a prescriber’s direction.
Pricing varies based on brand, generic availability, and pharmacy contracts. Generally, once a generic flecainide becomes widely available, its cost is lower than many newer, patented anti-arrhythmic agents, though exact figures depend on local NHS formulary decisions.
Maintaining a stable daily routine, limiting alcohol intake, and avoiding over-the-counter stimulants (e.g., high-dose caffeine) can help reduce the likelihood of arrhythmia triggers and support the medication’s efficacy.
Tambocor contains flecainide as its active component. Flecainide is a class Ic anti-arrhythmic medication used to treat certain abnormal heart rhythms. The drug is supplied as a pill in two strengths: 50 mg and 100 mg. In the United Kingdom, Tambocor is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is manufactured by [manufacturer information not provided]; the focus here is on the medication’s properties rather than brand-specific details.
Flecainide blocks fast-sodium channels in cardiac cells. By inhibiting the rapid influx of sodium during phase 0 of the cardiac action potential, it slows electrical conduction through the heart’s atria, ventricles, and His-Purkinje system. This effect:
Because the drug acts directly on the cardiac conduction system, it can quickly suppress certain supraventricular and ventricular arrhythmias. Onset of action usually occurs within a few hours after oral ingestion, with peak plasma concentrations reached in about 3 hours. The elimination half-life ranges from 12 to 27 hours, allowing once- or twice-daily dosing depending on the clinical situation.
Flecainide is approved in the UK for the following indications:
These uses reflect the drug’s ability to suppress rapid, irregular heartbeats while preserving overall cardiac output when applied appropriately.
Evidence from clinical studies and guideline statements suggests the following off-label uses, though they are not approved by the MHRA:
Off-label use requires medical supervision and individualized risk assessment.
Special populations such as the elderly may require dose reduction and closer observation due to altered drug metabolism.
Patients should provide a full medication list, including over-the-counter products and herbal supplements, to their healthcare provider before starting Tambocor.
If any concerning changes are detected, the prescriber may adjust the dose or discontinue the medication.
This article provides educational information about Tambocor and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
